Skip to main content

Market Overview

Addex Therapeutics' GABAB PAM Candidate Shows Potential For Alcohol Use Disorder

  • Addex Therapeutics (NASDAQ: ADXN) has announced that a review published in Alcohol and Alcoholism suggests that positive allosteric modulators (PAMs) of the gamma-aminobutyric acid B (GABAB) receptor could potentially offer a new treatment option for patients with severe alcohol use disorder.
  • Though GABAB receptor agonists, such as baclofen, have been shown to reduce addiction-related behaviors in preclinical studies. However, the therapeutic use of baclofen is minimal due to significant side-effects, including sedation, drowsiness, and sleepiness.
  • Addex's GABAB PAM, ADX71441, demonstrated efficacy on several alcohol-related behaviors in rat models and potently decreased binge-like drinking, reduced relapse-like drinking, and dose-dependently reduced alcohol self-administration as well as lowering motivation to consume alcohol.
  • Clinical studies are expected to start in 2022.
  • Price Action: ADXN stock increased 4.1% at $11.99 in market trading hours on the last check Tuesday.

Related Articles (ADXN)

View Comments and Join the Discussion!

Posted-In: alcohol addictionBiotech News General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at